All In Biotech

Drug Trial Radar · NCT06776952

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 10, 2025

Primary completion

Jan 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 days, up to 70 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.

Conditions

  • Relapsed/Refractory Peripheral T Cell Lymphoma

Interventions

  • XNW5004 ; Chidamide placeboDrug

    XNW5004 + Chidamide placebo

  • XNW5004 placebo; ChidamideDrug

    XNW5004 placebo + Chidamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) assessed by BICRTime frame: 24 mounths

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.